Structured page family:Cost guide
Lanreotide Cost Guide: Insurance, Cash Pay, and Savings
In the United States, Lanreotide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.
Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Somatuline Depot pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Lanreotide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.
Price Breakdown
List price (monthly)
~$4,000-$5,000/month
Average wholesale price
~$3,800-$4,800/month
Pharmacy acquisition estimate
~$3,500-$4,500/month
Typical negotiated rate
~$2,800-$3,800/month
Price per dose
~$4,000 per 120 mg injection
Annual cost at list price
~$48,000-$60,000
Pharmacy Price Comparison
| Pharmacy | Price Range | Notes |
|---|---|---|
| Specialty pharmacy | $3,800-$5,000/month | Required |
Insurance Coverage Landscape
Commercial plans
~80-90% for approved indications
Medicare Part D
May be Part B (administered in clinic)
Medicaid
Most states cover
VA coverage
On formulary
TRICARE
Covered
Employer plan typical tier
Tier 4-5 specialty; coinsurance 20-40%
Prior Authorization Guide
Required Documentation
- •Acromegaly: GH/IGF-1, MRI
- •NETs: pathology, imaging, receptor status
- •Specialist prescription
Common Denial Reasons
- •No biomarker confirmation
- •Off-label use
- •Not specialist-prescribed
Appeal Template Points
- •FDA-approved
- •Biochemical confirmation
- •Standard of care
- •CLARINET data for NETs
Expected timeline: 3-7 days
Savings Programs and Patient Assistance
Ipsen PAP
manufacturerEligibility: Uninsured, ≤400% FPL
Savings: Free
Income limit: ≤400% FPL
Enrollment: moderate
Annual
Copay assistance
copayEligibility: Commercially insured
Savings: May reduce significantly
Income limit: None
Enrollment: simple
Cap applies
Generic and Biosimilar Status
No generic currently available
Expected: No generic expected
Cost by Dose
| Dose/Regimen | Monthly | Annual |
|---|---|---|
| 90 mg monthly | $4,000 | $48,000 |
| 120 mg monthly | $5,000 | $60,000 |
Annual Cost Projection
Year 1
$0-$60,000
Year 2
$0-$60,000
Year 3
$0-$60,000
Assumptions
- •Chronic therapy
- •Insurance
Cost-Saving Strategies
- 1.Apply for Ipsen PAP if uninsured
- 2.Ensure biomarker documentation for smooth prior auth
- 3.Compare to octreotide pricing — choose based on efficacy and tolerability, not just cost
International Price Comparison
| Country | Price Range | Notes |
|---|---|---|
| UK | ~£500-700/month (~$630-880) | NHS |
Need help comparing lanreotide paths?
Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.
Find a lanreotide providerNext Step
Use the cost calculator
Use provider matching when you need help comparing insured and self-pay treatment paths.
Open tool →Retention Path
Join the Lanreotide tracker waitlist
Capture refill timing, weekly dose history, and symptom notes in one planned workflow.
View tracker landing →Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.
Lanreotide Cost FAQ
Sources
- 1. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.N Engl J Med • 2014Claim type: clinicalView source →
- 2. FDA Information on LanreotideFDA • 2026Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.